NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Stock Information for NanoViricides Inc.
Loading
Please wait while we load your information from QuoteMedia.